Acta Scientific Medical Sciences (ISSN: 2582-0931)

Review Article Volume 4 Issue 9

Parkinson’s Disease Patients with Dopamine Dysregulation Syndrome-Editorial Review

Hristina Popovska* and Igor Petrov

Department of Neurology, University SS. Cyril and Methodius, Macedonia

*Corresponding Author: Hristina Popovska, Department of Neurology, University SS. Cyril and Methodius, Macedonia.

Received: July 29, 2020; Published: August 26, 2020



Over the past decade, it has been identified a novel disease entity in patients with Parkinson’s disease, impulse-compulsive spectrum disorder. Dopamine dysregulation syndrome (DDS) included in this group, is a syndrome characterized for a patients treated with dopaminergic therapy, especially Levodopa. The phenomenology of this syndrome is in a close relation with the current understanding of the basal ganglia function and its impact on a long-term management in patients with Parkinson’s disease.

Patients treated with dopaminergic therapy, develop cognitive and behavioral disturbances besides motor symptoms. The PD therapy which basically is dopamine replacement therapy (DRT) can relieve the motor symptoms. On the other hand, recent studies show that the same therapy can be a cause of behavioral alterations, especially when it is abused by the patients. It is very important to differentiate the psychological symptoms whether they are related to the disease itself or are а side effect from the therapy.

Keywords: Dopamine Dysregulation Syndrome; Parkinson’s Disease; Psychiatric Symptoms



  1. Kenneth Blum., et al. “Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary”. Theoretical Biology and Medical Modeling 5 (2008): 24. 
  2. Warren N., et al. “Dopamine dysregulation syndrome in Parkinson’s disease: a systematic review of published cases”. Journal of Neurology, Neurosurgery, and Psychiatry 88 (2017): 1060-1064. 
  3. Eric Ch Wolters., et al. “Parkinson’s disease-related disorders in the impulsive-compulsive spectrum”. Journal of Neurology 255.5 (2008): 48-56.
  4. Roberto Ceravolo., et al. “Spectrum of addictions in Parkinson’s disease: from dopamine dysregulation syndrome to impulse control disorders”. Journal of Neurology 257.2 (2010): S276-S283.
  5. G Giovannoni., et al. “Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies”. Journal of Neurology, Neurosurgery, and Psychiatry 68 (2000): 423-428.
  6. K Blum., et al. “Neurogenetic Impairments of Brain Reward Circuitry Links to Reward Deficiency Syndrome (RDS): Potential Nutrigenomic Induced Dopaminergic Activation”. Journal of Genetics and Gene Therapy 3.4 (2012): 1000e115.
  7. Sean S O’Sullivan., et al. “Dopamine Dysregulation Syndrome. An Overview of its Epidemiology, Mechanisms and Menagement”. CNS Drugs 23 (2009): 157-170.
  8. Mahlon R DeLong and Thomas Wichmann. “Circuits and Circuit Disorders of the Basal Ganglia”. Archives of Neurology 64 (2007): 20-24.
  9. Andrew H Evans and Andrew J Lee. “Dopamine dysregulation syndrome in Parkinson’s disease: Editorial Review”. Current Opinion in Neurology 17 (2004): 393-398.
  10. Blum K and Kozlowski GP. “Ethanol and neuromodulator interactions: a cascade model of reward. Alcohol and Behavior”. Edited by: Ollat H, Parvez S, Parvez H. 1990, Utrecht, Netherlands: VSP Press (1990): 131-149.
  11. Malhotra AK., et al. “Genomics and the future of pharmacotherapy in psychiatry”. International Review of Psychiatry 19 (2007): 523-530.
  12. Carelli RM. “The nucleus accumbens and reward: neurophysiological investigations in behaving animals”. Behavioral and Cognitive Neuroscience Reviews 1 (2002): 281-296.
  13. Kurlan R. “Disabling repetitive behaviors in Parkinson’s disease”. Movement Disorders 19 (2004): 433-437.
  14. Voon V. “Repetition, repetition and repetition: Compulsive and punding behaviors in parkinson’s disease”. Movement Disorders 19 (2004): 367-370.
  15. Mia Zaharna MPH and Mayur Pandya. “Levodopa Addiction and Factitious Disorder in a Patient With Idiopathic Parkinson’s Disease”. The Journal of Neuropsychiatry and Clinical Neurosciences 22 (2010): 3.
  16. Anthony A Grace. “Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression”. Nature Reviews Neuroscience 17.8 (2016): 524-532.
  17. Leora L Borek and Joseph H Friedman. “Levodopa addiction in idiopathic Parkinson disease”. Neurology 65 (2005).
  18. Cilia R., et al. “Dopamine dysregulation syndrome in Parkinson’s disease: from clinical and neuropsychological characterization to management and long-term outcome”. Journal of Neurology, Neurosurgery, and Psychiatry 8 (2014): 311-318.
  19. Pezzella FR., et al. “Prevalence and clinical features of hedonistic homeostatic dysregulation in Parkinson’s disease”. Movement Disorder 20.1 (2005): 77-81.
  20. Ashok Sriram., et al. “Valproate as a treatment for dopamine dysregulation syndrome (DDS) in Parkinson's disease”. Journal of Neurology 260.2 (2013): 521-527. 
  21. Robinson TE and Berridge KC. “Addiction”. The Annual Review of Psychology 54 (2003): 25-53.
  22. Robinson TE and Berridge KC. “The psychology and neurobiology of addiction: an incentive-sensitization view”. Addiction 95.2 (2000): S91-S117.
  23. Xiao C., et al. “Effects of ethanol on midbrain neurons: role of opioid receptors”. Alcoholism: Clinical and Experimental Research 31 (2007): 1106-1113.
  24. Blum K., et al. “Reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive, and compulsive behaviors”. Journal of Psychoactive Drugs 32 (2000): i-iv.
  25. Li Y and Kauer JA. “Repeated exposure to amphetamine disrupts dopaminergic modulation of excitatory synaptic plasticity and neurotransmission in nucleus accumbens”. Synapse 51 (2004): 1-10.
  26. Kalivas PW and McFarland K. “Brain circuitry and the reinstatement of cocaineseeking behavior”. Psychopharmacology (Berl) 168 (2003): 44-56.
  27. Li Y., et al. “The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudate-putamen”. Neuropsychopharmacology 28 (2003): 1082-1085.
  28. Robbins TW and Everitt BJ. “Limbic-striatal memory systems and drug addiction”. Neurobiology of Learning and Memory 78 (2002): 625-636. 
  29. Evans AH., et al. “Punding in Parkinson’s disease: its relation to the dopamine dysregulation syndrome”. Journal of Movement Disorders 19 (2004): 397-405.
  30. Cools R., et al. “L-Dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson’s disease”. Neuropsychologia 41 (2003): 1431-1441.
  31. Emre M. “What causes mental dysfunction in Parkinson’s disease?” Journal of Movement Disorders 18.6 (2003): S63-S71.


Citation: Hristina Popovska and Igor Petrov. “Parkinson’s Disease Patients with Dopamine Dysregulation Syndrome-Editorial Review". Acta Scientific Medical Sciences 4.9 (2020): 90-96.


Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is April 30th, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue".
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US